{"id":"https://openalex.org/W2047273149","doi":"https://doi.org/10.3810/pgm.2010.09.2196","title":"Open-Label Administration of Lisdexamfetamine Dimesylate Improves Executive Function Impairments and Symptoms of Attention-Deficit/Hyperactivity Disorder in Adults","display_name":"Open-Label Administration of Lisdexamfetamine Dimesylate Improves Executive Function Impairments and Symptoms of Attention-Deficit/Hyperactivity Disorder in Adults","publication_year":2010,"publication_date":"2010-09-01","ids":{"openalex":"https://openalex.org/W2047273149","doi":"https://doi.org/10.3810/pgm.2010.09.2196","mag":"2047273149","pmid":"https://pubmed.ncbi.nlm.nih.gov/20861583"},"language":"en","primary_location":{"id":"doi:10.3810/pgm.2010.09.2196","doi":"https://doi.org/10.3810/pgm.2010.09.2196","is_oa":false,"landing_page_url":"https://doi.org/10.3810/pgm.2010.09.2196","pdf_url":null,"source":{"id":"https://openalex.org/S11800902","display_name":"Postgraduate Medicine","issn_l":"0032-5481","issn":["0032-5481","1941-9260"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Postgraduate Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025046256","display_name":"Thomas Edwards Brown","orcid":"https://orcid.org/0000-0001-7810-9821","observed_orcids":["https://orcid.org/0000-0001-7810-9821","https://orcid.org/0009-0003-1227-1334"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Thomas E. Brown","raw_affiliation_strings":["Associate Director, Yale Clinic for Attention and Related Disorders, Yale University School of Medicine, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Associate Director, Yale Clinic for Attention and Related Disorders, Yale University School of Medicine, New Haven, CT","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055799090","display_name":"Matthew N. Brams","orcid":"https://orcid.org/0000-0002-7926-6113","observed_orcids":["https://orcid.org/0000-0002-7926-6113"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthew Brams","raw_affiliation_strings":["Principal Investigator, Bayou City Research, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Principal Investigator, Bayou City Research, Houston, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101108686","display_name":"Joseph Gao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Gao","raw_affiliation_strings":["Director, Biostatistics, Clinical Development Operations and Biometrics, Shire Development Inc., Wayne, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Director, Biostatistics, Clinical Development Operations and Biometrics, Shire Development Inc., Wayne, PA","institution_ids":["https://openalex.org/I4210140176"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003133423","display_name":"Maria Gasior","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maria Gasior","raw_affiliation_strings":["Clinical Medicine Director, Shire Development Inc., Wayne, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Medicine Director, Shire Development Inc., Wayne, PA","institution_ids":["https://openalex.org/I4210140176"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5024208230","display_name":"Ann Catherine Childress","orcid":"https://orcid.org/0000-0001-5782-7891","observed_orcids":["https://orcid.org/0000-0001-5782-7891"]},"institutions":[{"id":"https://openalex.org/I4210146954","display_name":"Center for Psychiatry and Behavioral Medicine","ror":"https://ror.org/04tf0ye64","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210146954"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ann Childress","raw_affiliation_strings":["President, Center for Psychiatry and Behavioral Medicine, Las Vegas, NV"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"President, Center for Psychiatry and Behavioral Medicine, Las Vegas, NV","institution_ids":["https://openalex.org/I4210146954"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5025046256"],"corresponding_institution_ids":["https://openalex.org/I32971472"],"apc_list":null,"apc_paid":null,"fwci":2.686,"has_fulltext":false,"cited_by_count":29,"citation_normalized_percentile":{"value":0.88917918,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"122","issue":"5","first_page":"7","last_page":"17"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10537","display_name":"Attention Deficit Hyperactivity Disorder","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10537","display_name":"Attention Deficit Hyperactivity Disorder","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lisdexamfetamine-dimesylate","display_name":"lisdexamfetamine dimesylate","score":0.9700000286102295},{"id":"https://openalex.org/keywords/adult-adhd","display_name":"adult ADHD","score":0.6980000138282776},{"id":"https://openalex.org/keywords/executive-function","display_name":"executive function","score":0.8709999918937683},{"id":"https://openalex.org/keywords/stimulant-medication","display_name":"stimulant medication","score":0.5789999961853027},{"id":"https://openalex.org/keywords/adhd-rating-scale-iv","display_name":"ADHD Rating Scale-IV","score":0.7590000033378601},{"id":"https://openalex.org/keywords/dose-optimization","display_name":"dose optimization","score":0.847000002861023},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.9559999704360962},{"id":"https://openalex.org/keywords/working-memory","display_name":"working memory","score":0.6000000238418579},{"id":"https://openalex.org/keywords/self-regulation","display_name":"self-regulation","score":0.7559999823570251},{"id":"https://openalex.org/keywords/adhd-symptoms","display_name":"ADHD symptoms","score":0.3779999911785126},{"id":"https://openalex.org/keywords/open-label-extension","display_name":"open-label extension","score":0.44600000977516174},{"id":"https://openalex.org/keywords/stimulant-side-effects","display_name":"stimulant side effects","score":0.3919999897480011},{"id":"https://openalex.org/keywords/task-shifting","display_name":"task shifting","score":0.5709999799728394},{"id":"https://openalex.org/keywords/irritability","display_name":"irritability","score":0.5609999895095825}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6742008924484253},{"id":"https://openalex.org/C2780783007","wikidata":"https://www.wikidata.org/wiki/Q181923","display_name":"Attention deficit hyperactivity disorder","level":2,"score":0.6495673060417175},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5737211108207703},{"id":"https://openalex.org/C83849319","wikidata":"https://www.wikidata.org/wiki/Q7295720","display_name":"Rating scale","level":2,"score":0.5228043794631958},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5037636160850525},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.4548826515674591},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.4475376307964325},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4143930971622467},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.3367956876754761},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.3366340398788452},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.25642627477645874},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.24163231253623962},{"id":"https://openalex.org/C138496976","wikidata":"https://www.wikidata.org/wiki/Q175002","display_name":"Developmental psychology","level":1,"score":0.11270436644554138},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000069478","descriptor_name":"Lisdexamfetamine Dimesylate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000697","descriptor_name":"Central Nervous System Stimulants","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000697","descriptor_name":"Central Nervous System Stimulants","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001289","descriptor_name":"Attention Deficit Disorder with Hyperactivity","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003913","descriptor_name":"Dextroamphetamine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D003913","descriptor_name":"Dextroamphetamine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D056344","descriptor_name":"Executive Function","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.3810/pgm.2010.09.2196","doi":"https://doi.org/10.3810/pgm.2010.09.2196","is_oa":false,"landing_page_url":"https://doi.org/10.3810/pgm.2010.09.2196","pdf_url":null,"source":{"id":"https://openalex.org/S11800902","display_name":"Postgraduate Medicine","issn_l":"0032-5481","issn":["0032-5481","1941-9260"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Postgraduate Medicine","raw_type":"journal-article"},{"id":"pmid:20861583","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20861583","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Postgraduate medicine","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":43,"referenced_works":["https://openalex.org/W330186422","https://openalex.org/W332544700","https://openalex.org/W629283852","https://openalex.org/W1506869888","https://openalex.org/W1666727496","https://openalex.org/W1853960255","https://openalex.org/W1977936838","https://openalex.org/W1979206088","https://openalex.org/W1984462017","https://openalex.org/W1989415748","https://openalex.org/W1996061461","https://openalex.org/W1996783828","https://openalex.org/W1999461973","https://openalex.org/W2002430747","https://openalex.org/W2009357282","https://openalex.org/W2012696549","https://openalex.org/W2023262882","https://openalex.org/W2025163293","https://openalex.org/W2029500632","https://openalex.org/W2071199156","https://openalex.org/W2076504554","https://openalex.org/W2083905543","https://openalex.org/W2084038245","https://openalex.org/W2097184219","https://openalex.org/W2106131177","https://openalex.org/W2110145837","https://openalex.org/W2112429654","https://openalex.org/W2121027929","https://openalex.org/W2123910896","https://openalex.org/W2127512142","https://openalex.org/W2129620184","https://openalex.org/W2138210540","https://openalex.org/W2144579914","https://openalex.org/W2154109950","https://openalex.org/W2157953466","https://openalex.org/W2159184227","https://openalex.org/W2159881136","https://openalex.org/W2164676183","https://openalex.org/W2167875798","https://openalex.org/W2376967457","https://openalex.org/W2585172482","https://openalex.org/W2993504029","https://openalex.org/W4255396331"],"related_works":["https://openalex.org/W2046461248","https://openalex.org/W1997255333","https://openalex.org/W2324047828","https://openalex.org/W1992717477","https://openalex.org/W3031999107","https://openalex.org/W2318134686","https://openalex.org/W2076699588","https://openalex.org/W3175616451","https://openalex.org/W2087643483","https://openalex.org/W2319564505"],"abstract_inverted_index":{"INTRODUCTION/OBJECTIVE:":[0],"Executive":[1,78],"function":[2,79],"(EF)":[3],"impairment":[4],"in":[5,22,52,61,122,286],"attention-deficit/hyperactivity":[6],"disorder":[7],"(ADHD)":[8],"may":[9],"account":[10],"for":[11],"behavioral":[12,124],"symptoms":[13,125],"such":[14],"as":[15],"poor":[16],"concentration,":[17],"impaired":[18],"working":[19],"memory,":[20],"problems":[21],"shifting":[23],"among":[24,142],"tasks,":[25],"and":[26,28,44,67,134,155,158,187,231,270],"prioritizing":[27],"planning":[29],"complex":[30],"sets":[31],"of":[32,46,71,105,138,221,228,278],"tasks":[33],"or":[34,40,162,172],"completing":[35],"long-term":[36,301],"projects":[37],"at":[38,65],"work":[39],"school.":[41],"Poor":[42],"self-regulation":[43],"control":[45],"emotional":[47],"behaviors":[48,60,285],"frequently":[49],"are":[50],"seen":[51],"patients":[53],"with":[54,63,73,115,144,205,288,293,297,300],"ADHD.":[55,289],"This":[56],"study":[57,104],"assessed":[58,82,118],"EF":[59,123,284],"adults":[62,287],"ADHD":[64,110,119],"baseline":[66,141,165,199],"after":[68],"4":[69,131],"weeks":[70],"treatment":[72],"lisdexamfetamine":[74],"dimesylate":[75],"(LDX).":[76],"METHODS:":[77],"behavior":[80],"was":[81,126],"using":[83],"the":[84,91,245],"Brown":[85],"Attention-Deficit":[86],"Disorder":[87],"Scale":[88,112],"(BADDS)":[89],"during":[90,244],"4-week":[92],"open-label":[93],"dose-optimization":[94,246],"phase":[95,247],"prior":[96],"to":[97,150,153],"a":[98,224],"2-period,":[99],"randomized,":[100],"double-blind,":[101],"placebo-controlled":[102],"crossover":[103],"LDX":[106,279,294],"(30-70":[107,280],"mg/day).":[108],"The":[109,203],"Rating":[111],"IV":[113],"(ADHD-RS-IV)":[114],"adult":[116,206],"prompts":[117,207],"symptoms.":[120],"Change":[121],"evaluated":[127],"based":[128],"on":[129],"week":[130,183,218],"BADDS":[132,145,185,225],"total":[133,186,226],"cluster":[135,188],"scores;":[136],"analyses":[137],"shifts":[139],"from":[140],"subjects":[143,222],"scores":[146,159,189,208],"<":[147,196,213,229],"50,":[148,230],"50":[149],"59,":[151],"60":[152],"69,":[154],"\u2265":[156],"70;":[157],"less":[160],"than":[161,164],"greater":[163],"90%":[166],"confidence":[167],"range":[168],"(eg,":[169],"reliably":[170,234,238],"improved":[171,210,283],"worsened,":[173],"respectively).":[174],"Treatment-emergent":[175,290],"adverse":[176,291],"events":[177,292],"(TEAEs)":[178],"were":[179,190,233,237,248,295],"described.":[180],"RESULTS:":[181],"At":[182,217],"4,":[184,219],"reduced":[191],"(ie,":[192],"improved;":[193,235],"all":[194],"P":[195,212],"0.0001":[197,214],"vs":[198,215],"[n":[200],"=":[201],"127]).":[202],"ADHD-RS-IV":[204],"also":[209],"(all":[211],"baseline).":[216],"62.7%":[220],"had":[223],"score":[227],"78.9%":[232],"1.4%":[236],"worsened.":[239],"Common":[240],"TEAEs":[241],"(\u2265":[242],"5%)":[243],"decreased":[249],"appetite":[250],"(36.6%),":[251],"dry":[252],"mouth":[253],"(30.3%),":[254],"headache":[255],"(19.7%),":[256],"insomnia":[257],"(18.3%),":[258],"upper":[259],"respiratory":[260],"tract":[261],"infection":[262],"(9.9%),":[263],"irritability":[264],"(8.5%),":[265],"nausea":[266],"(7.7%),":[267],"anxiety":[268],"(5.6%),":[269],"feeling":[271],"jittery":[272],"(5.6%).":[273],"CONCLUSION:":[274],"Clinically":[275],"optimized":[276],"doses":[277],"mg/day)":[281],"significantly":[282],"consistent":[296],"those":[298],"observed":[299],"stimulant":[302],"use.":[303]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}